Genta Tests Drug Targeting Cancer Gene
Posted on: Friday, 13 October 2006, 12:00 CDT
U.S. firm Genta said Friday it has begun a phase 1 study of a new cancer drug that targets a key gene in cancer cell growth.
The investigational therapy -- dubbed G4460 -- uses antisense technology to target an oncogene called c-myb that is responsible for regulating key functions in cancer cells.
The study -- to be conducted at the General Clinical Research Center at the University of Pennsylvania in Philadelphia -- is designed to assess appropriate dosing, safety, biologic activity, and down-regulation of the gene c-myb in patients with advanced hematologic cancers.
The c-myb proto-oncogene regulates a number of proteins that are critical for growth of cancer cells, Alan Gewirtz, professor of medicine and pathology at the University of Pennsylvania School of Medicine, said in a statement issued by the company. Preclinical studies have shown that disruption of c-myb has antitumor effects, and this new trial seeks to evaluate whether these effects can be translated into an effective therapeutic strategy for patients.
Source: United Press International
Related Articles
- New Cancer Gene Discovered
- Estrogen Can Switch on Breast Cancer Gene
- Antisense Drug Targeting C-Myb Oncogene Starts Phase 1 Trial in Patients With Advanced Cancer
- Altered Smallpox Vaccine May Fight Cancer
- Acupuncture May Have Place in Breast Cancer Treatment
- Acupuncture a Salve for Colorectal Cancer?
- Abortion-Breast Cancer Link Deemed Untrue
- 'Sonic Hedgehog' Holds Clue to Lung Cancer
- Abortion, Breast Cancer Link Discounted
 |
 |
User Comments (0)
RSS Feeds